Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
Maciocia PM, Wawrzyniecka PA, Maciocia NC, Burley A, Karpanasamy T, Devereaux S, Hoekx M, O'Connor D, Leon T, Rapoz-D'Silva T, Pocock R, Rahman S, Gritti G, Yánez DC, Ross S, Crompton T, Williams O, Lee L, Pule MA, Mansour MR. Maciocia PM, et al. Blood. 2022 Jul 7;140(1):25-37. doi: 10.1182/blood.2021013648. Blood. 2022. PMID: 35507686 Free article.
Anti-CD1a CAR T cells to selectively target T-ALL.
Maciocia PM, Pule MA. Maciocia PM, et al. Blood. 2019 May 23;133(21):2246-2247. doi: 10.1182/blood-2019-03-900910. Blood. 2019. PMID: 31122936 Free article. No abstract available.
Chimeric antigen receptor T cells for gamma-delta T cell malignancies.
Wawrzyniecka PA, Ibrahim L, Gritti G, Pule MA, Maciocia PM. Wawrzyniecka PA, et al. Among authors: maciocia pm. Leukemia. 2022 Feb;36(2):577-579. doi: 10.1038/s41375-021-01385-0. Epub 2021 Aug 13. Leukemia. 2022. PMID: 34389804 Free PMC article. No abstract available.
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.
Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, Ma B, Bughda R, Akbar Z, Srivastava S, Gannon I, Robson M, Sillibourne J, Jha R, El-Kholy M, Amin OM, Kokalaki E, Banani MA, Hussain R, Day W, Lim WC, Ghongane P, Hopkins JR, Jungherz D, Herling M, Welin M, Surade S, Dyson M, McCafferty J, Logan D, Cordoba S, Thomas S, Sewell A, Maciocia P, Onuoha S, Pule M. Ferrari M, et al. Nat Commun. 2024 Feb 21;15(1):1583. doi: 10.1038/s41467-024-45854-3. Nat Commun. 2024. PMID: 38383515 Free PMC article.
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S, Maciocia P, Popat R, D'sa S, Rismani A, Cerner A, Yong K, Rabin N. Maciocia N, et al. Br J Haematol. 2017 Mar;176(6):908-917. doi: 10.1111/bjh.14547. Epub 2017 Feb 17. Br J Haematol. 2017. PMID: 28211054 Free article.
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
Chavda SJ, Maciocia PM, Mesiri P, Counsell N, Kothari J, Bird A, Mariner C, Chew A, Clesham K, Moore S, Percy L, Rismani A, D'Sa S, Rabin N, Popat R, Yong K. Chavda SJ, et al. Among authors: maciocia pm. Br J Haematol. 2019 Apr;185(2):350-353. doi: 10.1111/bjh.15487. Epub 2018 Jul 9. Br J Haematol. 2019. PMID: 29984833 Free article. No abstract available.
13 results